Head of Pfizer booed by Trump supporters
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...
Dr. Albert Bourla is also troubled by this ... “It’s a great, great honor, which I accept on behalf of everyone at Pfizer,” said Bourla. In its announcement, the Foundation highlighted ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...
Dividend payers are solid performers. One reason is that a company has to reach a point where it has some fairly dependable ...
Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback